Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Thrombotic biomarkers and angiographic characteristics were compared among the de novo patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV) and the control.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Central serous chorioretinopathy | De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis. |
| |
| Polypoidal choroidal vasculopathy | De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis. |
| |
| Epiretinal membrane | Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sampling | Other | Sampling the blood including DNA to investigate the thrombotic profile |
|
| Measure | Description | Time Frame |
|---|---|---|
| Serum Fibrinogen in active PCV and CSC patients | Serum Fibrinogen (mg/dl) | Less than 1 week after initial diagnosis |
| Serum Factor VIII activity in active PCV and CSC patients | Serum Factor VIII activity (%) | Less than 1 week after initial diagnosis |
| Serum Plasminogen activity in active PCV and CSC patients | Serum Plasminogen activity (%) | Less than 1 week after initial diagnosis |
| Serum D-dimer in active PCV and CSC patients | Serum D-dimer (μg/mL(FEU)) | Less than 1 week after initial diagnosis |
| Serum Fibrin degradation product in active PCV and CSC patients | Serum Fibrin degradation product (μg/mL) | Less than 1 week after initial diagnosis |
| Serum PAI-1 antigen in active PCV and CSC patients | Serum PAI-1 (plasminogen activator inhibitor-1) antigen (ng/mL) | Less than 1 week after initial diagnosis |
| Serum PAI-1 SNP genotyping in active PCV and CSC patients | Serum PAI-1 SNP(single nucleotide polymorphism) genotyping | Less than 1 week after initial diagnosis |
| Measure | Description | Time Frame |
|---|---|---|
| Characteristics of fluorescein angiography in active PCV and CSC patients | Numbers of leaking points of fluorescein dye in fluorescein angiography | Less than 1 week after initial diagnosis |
| Characteristics of indocyanine green angiography in active PCV and CSC patients |
Not provided
Inclusion Criteria:
CSC
PCV
Control
Exclusion Criteria:
Not provided
Not provided
De novo patients with active CSC and PCV.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Se Woong Kang, MD | Contact | +82-2-3410-3548 | swkang@skku.edu |
| Name | Affiliation | Role |
|---|---|---|
| Kunho Bae, MD | Department of ophthalmology, Samsung medical center, Seoul, Korea | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Samsung Medical Center | Recruiting | Seoul | 06351 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D056833 | Central Serous Chorioretinopathy |
| D000092342 | Polypoidal Choroidal Vasculopathy |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D020256 | Choroidal Neovascularization |
| D015862 | Choroid Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples including DNA will be retained to perform the genotyping analysis of PAI-1 SNP.
Numbers of hyperfluorescent spots in indocyanine green angiography |
| Less than 1 week after initial diagnosis |
| D014603 |
| Uveal Diseases |
| D009389 | Neovascularization, Pathologic |
| D008679 | Metaplasia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |